Anagram Therapeutics
Summary active Updated May 8, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Anagram Therapeutics is a clinical-stage private biopharmaceutical company headquartered in Natick, Massachusetts, dedicated to improving the lives of people living with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, pancreatic cancer, and related disorders 1. The company’s lead candidate, ANG003, is a novel orally delivered recombinant enzyme replacement therapy designed to reduce the daily pill burden — patients currently take up to 40 capsules per day, while ANG003 is intended to require only one tablet per meal 1 2. The company is led by President and CEO Robert Gallotto 1.
ANG003 has demonstrated positive clinical data in people with EPI due to cystic fibrosis, and Anagram is initiating an international Phase II trial following its earlier ANG003-22-101 study 1 3. Prior to the 2026 Blackstone investment, the Cystic Fibrosis Foundation contributed more than $30 million in non-dilutive funding to support clinical and development work on ANG003 1 2.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-05-07 | Growth | $250M | Blackstone Life Sciences | — 1 2 3 4 |
Note: The Cystic Fibrosis Foundation previously contributed more than $30M in non-dilutive grant funding for ANG003 development prior to this round 1.
What Investors Say
“We believe Anagram is well positioned to transform the treatment of pancreatic insufficiency, especially in patients of all ages who suffer from cystic fibrosis.”
— Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences 1
What Founders Say
“The clinical data generated from the ANG003-22-101 study in patients with EPI due to CF is compelling.”
— Robert Gallotto, President and CEO, Anagram Therapeutics 1
Sources
-
Blackstone press release, “Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency,” May 7, 2026, accessed May 2026. https://www.blackstone.com/news/press/blackstone-life-sciences-invests-250-million-in-anagram-therapeutics-to-advance-novel-and-patient-friendly-oral-enzyme-replacement-therapy-for-pancreatic-insufficiency/↩↩↩↩↩↩↩↩↩
-
BioSpace, “Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics,” May 7, 2026, accessed May 2026. https://www.biospace.com/press-releases/blackstone-life-sciences-invests-250-million-in-anagram-therapeutics-to-advance-novel-and-patient-friendly-oral-enzyme-replacement-therapy-for-pancreatic-insufficiency↩↩↩
-
Endpoints News, “Blackstone puts $250M into Anagram to tackle cystic fibrosis complication,” May 7, 2026, accessed May 2026. https://endpoints.news/blackstone-puts-250m-into-anagram-to-tackle-cystic-fibrosis-complication/↩↩
-
Crunchbase News, “The Biggest Funding Rounds: Sierra, Astrani, Anagram Therapeutics,” accessed May 2026. https://news.crunchbase.com/venture/biggest-funding-rounds-sierra-astrani-anagram-therapeutics/↩